| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 10, 2025 | I Want A New Drug. A Vaccine Even. And A Functioning FDA, CDC, NIH, Etc… | My cancer is back. This is disappointing but not unexpected; of the 2/3 of people who survive their first bout with ovarian cancer, 80% usually have it recur at some point. For me it was sooner than expected, and disheartening because, even... |
| Dec 17, 2024 | Akamis Bio Raises $60M in Funding | Akamis Bio, a Cambridge, MA-based clinical-stage oncology company, raised $60M in funding.
The round was led by Sedgwick Yard.
The company intends to use the funds to support its work to advance NG-350A through a Phase 1b clinical proof-of-... |
| Nov 8, 2024 | Infinitopes: Pioneering the Future of Cancer Vaccines | In the world of cancer treatment, hope often feels like a flickering candle in a storm. Yet, a new player is emerging, determined to turn that flicker into a blazing beacon. Infinitopes, a biotech company born from the halls of Oxford Unive... |
| Nov 8, 2024 | The Future of Vision and Immunotherapy: Innovations from AllFocal Optics and Infinitopes | In the world of technology and healthcare, two companies are pushing boundaries. AllFocal Optics and Infinitopes are not just making waves; they are creating tsunamis of innovation. Each is tackling a unique challenge: enhancing human visio... |
| Nov 8, 2024 | Infinitopes to Showcase Breakthroughs on Cancer Vaccine Development at SITC 2024: Insight into a double-blind, Phase I/IIa clinical trial | Infinitopes' lead vaccine candidate ITOP1 is a novel, precision targeted, immunologically durable, "off-the-shelf" cancer vaccine, designed to save lives by preventing disease recurrence in first-line patients with surgically rese... |
| Aug 16, 2024 | A New Dawn in Cancer Research: AI and Funding Unite for Hope | In the battle against cancer, innovation is the sword and funding is the shield. Two recent developments highlight this truth: a groundbreaking collaboration between Absci Corporation and Memorial Sloan Kettering Cancer Center (MSK), and a ... |
| Aug 15, 2024 | The Lustgarten Foundation Announces Landmark Year of Fueling Cutting-Edge Pancreatic Cancer Research | The Lustgarten Foundation is the largest private funder of pancreatic cancer research in the world, fueling preeminent researchers and driving bold, innovative science toward better treatments.
The Lustgarten Foundation, the nation's larges... |
| May 6, 2024 | OverT Bio Secures $16M to Optimize Cell Therapy for Solid Tumors | What You Should Know:
– OverT Bio, a data-driven biotech company focused on unlocking the curative potential of cell therapies for solid tumors raises $16M in seed funding round. Co-led by ARTIS Ventures and Wing VC, the round saw participa... |
| Oct 18, 2022 | SURGE Therapeutics Raises $26M to Accelerate Intraoperative Immunotherapy | What You Should Know:
SURGE Therapeutics (The Intraoperative Immunotherapy Company™) seeks to dramatically improve cancer patient survival by disrupting how, when, and where cancer immunotherapy is deployed.
While surgery is the standard of... |
| Jun 1, 2021 | Janssen Pharmaceuticals : Announces U.S. FDA Breakthrough Therapy Designation Granted for Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma | News Release
Media Contacts:
Brian Kenney
Phone: +1 215-620-0111
Satu Glawe
Phone: +49 172-294 6264
Investor Relations:
Jennifer McIntyre
Office: +1 732-524-3922
U.S. Medical Inquiries:
+1 800-526-7736
Janssen Announces U.S. FDA Breakthroug... |
| Jun 16, 2020 | By phone, cancer patients reveal their Covid-19 angst — and seek help | Clinical trials have always represented hope for people with cancer. Whether someone is newly diagnosed or has exhausted most treatment options, trials can provide a crucial, alternate treatment. Covid-19 has upended that lifeline, along wi... |
| Sep 5, 2019 | Goldman Sachs has poached a top credit trader from a $30 billion hedge fund to jumpstart its high-yield trading business | Chris Hondros/Getty Images
Advertisement
Goldman Sachs has poached a senior trader from $30 billion hedge fund Anchorage Capital.
Drew Goldman, 37, is departing Anchorage and joining the investment bank as a managing director in its high-yi... |
| Sep 4, 2019 | Enough with the me-too drugs. New treatments should be worthy of the people who invest their lives in clinical trials | Like many people starting out in the biotech industry, I wanted to make an impact on people’s lives by developing life-changing therapies. But I’ve become disappointed by what I believe are too many companies pushing mediocre and me-too dru... |
| Nov 29, 2018 | The number of I/O cancer drugs in the clinic continues to swell at an explosive pace -- offering new hope, fresh concerns | The juggernaut of immuno-oncology drug research around the world continues to rapidly gain speed and mass, offering patients with virtually every cancer type the prospect of new combinations or monotherapies that may b... |
| Oct 1, 2018 | The snub club: Crucial contributors to cancer immunotherapy were excluded from the medicine Nobel | The Nobel committee’s account of discoveries critical to harnessing the immune system to treat cancer lists just under 100 papers authored by hundreds of scientists. But the message that “it takes a village” to move a discovery in basic sci... |
| Oct 1, 2018 | A pioneer in cancer immunotherapy sees a future where vaccines, CAR-T, and checkpoint inhibitors come together | Dr. Padmanee Sharma was in a rush: On Sunday afternoon she had just finished giving her speech as the winner of the William B. Coley Award for outstanding research in tumor immunology, her cousin was in labor in Sharma’s New York City hotel... |
| Jun 22, 2018 | We need more answers about immunotherapy for the elderly | An old idea — using the body’s immune system to fight cancer cells, first proposed more than a century ago — has become one of the most promising approaches to treating cancer today. Immunotherapy is effective against a variety of cancers, ... |
| Jan 10, 2018 | Biopharma watchers arrive at rare consensus: 2018 will be big year for M&A | Not one person said they expect total M&A activity to decline in the coming year, relative to 2017. Just over 12 percent predicted deal activity would be comparable; the rest are expecting some sort of buying spree.
Why?
It’s not rocket... |
| Nov 8, 2017 | Can a math model help predict an immune response to cancer? | The authors describe a first-of-its-kind mathematical model for predicting how a cancer patient will benefit from checkpoint inhibitors, a class of drugs that includes Merck’s Keytruda and Bristol Myers-Squibb’s Opdivo.
Checkpoint inhibitor... |
| Aug 2, 2017 | The hidden power of nonprofits in the struggle against cancer | That convening power was one of the takeaways from a longer discussion about how nonprofits organize education campaigns, encourage clinical trials, and share data, all in the name of supporting researchers, hospitals, and the pharmaceutica... |
| Jan 11, 2017 | How do we solve the crisis in cancer communication? | Five rounds of the usual chemotherapy/radiation protocol kept Alan Gross alive through decades of living with lymphoma. The treatments were grueling, but he was living proof that science was giving us ways to live with cancer. Then the dise... |
| Dec 1, 2016 | Sean Parker is partnering with the Cancer Research Institute to find a cancer vaccine | Cancerous tumors carry certain markers called neoantigens and Facebook billionaire Sean Parker wants to use algorithms to find them.
To do so, the Parker Institute for Cancer Immunotherapy will work with more than 30 public and private phar... |
| Oct 25, 2016 | Balance of power shifts with Merck’s Keytruda first-line therapy approval in lung cancer | Total sales of Keytruda in 2015 reached $566 million, compared to $942 million by Opdivo. However, following Monday’s announcement, Bernstein analysts forecast an additional $1 billion in sales for Keytruda in 2017.
Another analyst agreed.
... |
| Jul 21, 2016 | First CRISPR trial in humans is reported to start next month | Scientists in China plan to use the genome-editing technology CRISPR-Cas9 in patients as early as next month, Nature reported on Thursday. If they go ahead, it would be the first time people would be injected with cells whose DNA has been a... |
| Feb 9, 2016 | Aurora Biopharma tackling glioblastoma with CAR-T immunotherapy; plans to raise $20M | “We believe in having multiple antigens, not just one,” Brooks said. “We’re involved in bispecific and trispecific antigens.”
So far, Aurora been operating largely on some $15 million in grant funding, from the NIH and various charities. It... |
| Feb 5, 2015 | TrialReach raises $13.5m series B led by Smedvig Capital | TrialReach raises $13.5m series B led by Smedvig Capital
05-02-2015
Funding will fuel TrialReach’s clinical trial platform growth and expansion into the U.S.
TrialReach, the world’s largest provider of clinical trial information, today anno... |
| Feb 5, 2015 | TrialReach raises $13.5m series B led by Smedvig Capital | Funding will fuel TrialReach’s clinical trial platform growth and expansion into the U.S.
TrialReach, the world’s largest provider of clinical trial information, today announced it has raised a $13.5M Series B financing round led by Smedvig... |
| A top biotech VC shares the 3 criteria startups need to survive the market meltdown | Josh Wolfe, a managing partner and cofounder of Lux Capital. Lux Capital This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
A top VC shared three necessities for startups in the biotech mark... |
| Aurora Biopharma tackling glioblastoma with CAR-T immunotherapy; plans to raise $20M | A new contender is emerging in the glioblastoma space: Cambridge startup Aurora Biopharma is developing a CAR-T immunotherapy to treat this aggressive form of brain cancer. It’s looking to raise a $20 million Series A round, CEO Robert Broo... |
| The future of immunotherapy starts here | Few scientific advances have transformed cancer care as quickly or broadly as cancer immunotherapy. In little over a decade, a series of innovative immunotherapies have improved outcomes for patients with some of the most daunting cancers, ... |
| The hidden power of nonprofits in the struggle against cancer | From left: Katie Thiede of Bright Pink, Jill O’Donnell-Tormey of Cancer Research Institute, and Martin Murphy of CEO Roundtable on Cancer
Nonprofits have a special authority, the power to bring people together, and it’s that ability that ma... |
| COVID-19 vaccines revolutionized RNA — now everyone else wants in | Employees in special suits test procedures for manufacturing the messenger-RNA COVID-19 vaccine from Pfizer-BioNTech in Marburg, Germany, on March 29. Abdulhamid Hosbas/Anadolu Agency via Getty Images This story is available exclusively to ... |
| Targovax ASA: LUDWIG CANCER RESEARCH AND CANCER RESEARCH INSTITUTE PARTNER WITH TARGOVAX TO TEST CANDIDATE VIROTHERAPY IN EARLY-PHASE CLINICAL TRIALS | November 18, 2015, New York, NY and Oslo, Norway – Ludwig Cancer Research and the Cancer Research Institute (CRI) announced today an agreement with the biotechnology company Targovax to evaluate its experimental virotherapy, ONCOS-102, in e... |
| Cell therapy has revolutionized cancer treatment. Now the California biotech Sangamo is trying to see if it can also upend autoimmune diseases. | Scientists in the lab at Sangamo Therapeutics. Sangamo Therapeutics This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
California biotech Sangamo Therapeutics has given its first doses of an... |
| Can a math model help predict an immune response to cancer? | Why do some immunotherapies work in certain patients and not others? It’s a multi-million dollar question, which researchers at the Icahn School of Medicine at Mount Sinai are hoping to solve with some custom computer modeling.
Their work a... |
| Balance of power shifts with Merck’s Keytruda first-line therapy approval in lung cancer | Merck’s immunotherapy drug Keytruda can now be sold as a first-line therapy for certain metastatic non-small cell lung cancer (NSCLC) patients — an industry-first that once again shifts the balance of power in the anti-PD-L1 therapy duel.
T... |
| Big Pharma is betting billions on the next cancer breakthrough. Here are the 14 drug companies leading the way. | Getty Images This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Redeem now
Drug-industry giants are betting billions on one of the hottest targets in cancer research.
Researchers hope drugs ... |
| Merck CEO says public service is in his future, but not politics, as he plans June retirement | Merck CEO Ken Frazier plans to retire at the end of June.
He’ll be succeeded by CFO Robert Davis.
Frazier spoke with CNBC about his legacy at Merck and what comes next. |
| Biopharma watchers arrive at rare consensus: 2018 will be big year for M&A | The Boston Consulting Group (BCG) hosted its annual “Value Creation in Health Care” breakfast on Tuesday during J.P. Morgan week in San Francisco bringing together more than 100 senior executives and analysts from various healthcare sectors... |
